Back to results
US 2017/0362243 A1Published application
Biarylether imidazopyrazine btk inhibitors
AssigneeMerck Sharp & Dohme Corp.
InventorsJIAN LIU, JOSEPH A. KOZLOWSKI, SOBHANA BABU BOGA, XIAOLEI GAO, DEODIAL GUY GUIADEEN, JYHSHING WANG, SHILAN LIU
Life of this patent
Estimating the term…
Abstract
The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
Claims12
A compound according to Formula I, or a pharmaceutically acceptable salt thereof
- wherein:
- R1 is hydrogen or halogen;
- X is selected from the group consisting of:
- a) cycloalkyl;
- b) cycloalkylmethylene;
- c) cycloalkenyl;
- and
- d) heterocycloalkyl;
- each optionally substituted with one, two or three (1-6C)alkyl groups.
6 more elements
Dependencies are inferred from the claim text.